CINGW Stock Overview: Comprehensive Insights on Cingulate Inc. Shares

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

Altman Z Score 2,970.54
Piotroski Score 4.00
Grade N/A

Company brief: Cingulate Inc. (CINGW)

Sector Healthcare
Industry Biotechnology
CEO Dr. Shane J. Schaffer Pharm.D.
Website https://www.cingulate.com
Country US
Employees (FY) 13
Founded N/A
ISIN US17248W1137

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.

Price Target and Rating

Average Stock Price Target $0.00
High Stock Price Target $0.00
Low Stock Price Target $0.00
Potential Upside/Downside N/A
Consensus Rating Sell
Rating Score (0-4) N/A
Research Coverage N/A

Profitability

EPS (Most Recent Fiscal Year) -$1.73
Trailing P/E Ratio -0.01
Forward P/E Ratio -0.01
P/E Growth -0.01
Net Income $-23,534,947

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Cingulate Inc. (CINGW) Stock Price, News & Analysis

Stock Score/grades

Company brief: Cingulate Inc. (CINGW)

Price Target and Rating

Profitability

Key Stats

Select an alert type

Setup alert

Log In

Email Verification

Welcome to StockNews!

Create Your Account

Email Verification